RESEARCH UPDATE · HUMAN LACTATION DATA
Does Tirzepatide Pass Into Breast Milk? What the Human Studies Found
Two small human lactation studies found tirzepatide was usually undetectable or present only at very low measured levels in breast milk. Here is what those results show—and what remains unknown.
Short answer: Research on tirzepatide and breast milk is limited. Two small human lactation studies found that tirzepatide—a dual GIP and GLP-1 receptor agonist—was usually undetectable or present only at very low levels in breast milk under the conditions tested. That is useful pharmacokinetic evidence, but it does not prove that tirzepatide is safe for every breastfed infant. The studies were small, and the strongest manufacturer study used one 5 mg dose rather than repeated steady-state dosing.
This research involved lactating adults, not pregnant participants. It cannot answer questions about exposure during pregnancy, fetal development, milk production, long-term infant development, or higher repeated doses.
What did the FDA-label lactation study find?
The current FDA prescribing information for Zepbound summarizes a single-dose clinical lactation study in 11 healthy lactating adults. Each participant received one 5 mg subcutaneous dose of tirzepatide, and investigators collected milk samples over 28 days.
According to the FDA-approved label:
- tirzepatide was undetectable in 164 of 171 milk samples using an assay with a 4 ng/mL detection limit;
- the remaining seven samples contained a cumulative amount equivalent to less than 0.02% of the maternal dose;
- the last measurable concentrations occurred five days after dosing; and
- there were too few quantifiable concentrations to calculate the milk concentration-time area under the curve.
The matching ClinicalTrials.gov record for NCT05978713 shows that all 11 participants completed the study. It also confirms that the planned primary milk-exposure measure could not be calculated because concentrations were generally below the assay’s detection limit.
Those findings support a narrow conclusion: after a single 5 mg dose, measured transfer into milk was low under the study’s sampling and assay conditions.
They do not establish infant safety. The protocol required participants to stop breastfeeding during the 29-day post-dose study period, so the study did not directly expose or follow nursing infants.
What did the repeated-dosing preprint find?
A separate 2025 preprint examined milk from five lactating participants who were already using subcutaneous tirzepatide at 2.5 to 5 mg per week. Investigators used liquid chromatography–high-resolution mass spectrometry, with a reported detection limit of 0.7 ng/mL and quantification limit of about 2.4 ng/mL.
The authors reported that tirzepatide was not quantifiable in any collected sample. Some signals were below the detection threshold, but none exceeded the assay’s quantification threshold. One participant supplied a sample 168 hours after dosing.
This dataset is useful because it examined people receiving repeated weekly doses rather than a single administered dose. It also differs from the manufacturer study because participants continued breastfeeding to varying degrees. The authors reported no infant adverse effects that the mothers attributed to tirzepatide.
However, the paper remains a preprint and has not been peer reviewed. It included only five participants, had no untreated comparison group, and relied on limited sampling and maternal reports rather than a controlled infant-safety assessment. “No adverse effects were reported” should not be read as proof that adverse effects cannot occur.
The two studies answer different questions
| Study | Participants and exposure | Milk finding | What it cannot establish |
|---|---|---|---|
| Manufacturer/FDA-label study | 11 lactating adults; one 5 mg dose | 164/171 samples undetectable; total detected in seven samples was less than 0.02% of the maternal dose | Steady-state accumulation, repeated higher doses, infant effects, or effects on milk production |
| Independent preprint | Five lactating participants; 2.5–5 mg weekly | No sample exceeded the reported quantification limit | Population-wide safety, uncommon effects, long-term infant outcomes, or a causal safety conclusion |
Taken together, the studies point in the same direction: measured tirzepatide levels in milk were generally below detection or quantification limits. Their designs and assay thresholds were different, though, so their numbers should not be combined as if they came from one trial.
“Undetectable” does not mean zero
Laboratory assays have limits. If a result is below an assay’s limit of detection, the study did not reliably distinguish the drug signal from background at concentrations below that threshold. A result below the limit of quantification may indicate a signal too small to measure accurately.
That means “undetectable” is not the same as demonstrating that exactly zero tirzepatide entered milk. It means the concentration, if present, was below what that particular method could reliably detect.
The FDA label appropriately describes tirzepatide as either undetectable or low in milk. It does not say that transfer is impossible.
Why the single-dose limitation matters
Tirzepatide has an elimination half-life of roughly five days and is normally administered weekly. Repeated dosing can produce accumulation before steady state is reached.
The FDA-label study administered only one 5 mg dose. LactMed therefore cautions that the single-dose study does not account for the accumulation expected during typical repeated use and that milk amounts at steady state could be higher than the single-dose findings indicate.
The five-person preprint offers limited repeated-dose information, but its small size and sampling design cannot fully characterize milk concentrations across dose escalation, higher maintenance doses, early postpartum physiology, or a broad population.
What remains unknown?
The existing studies leave several important questions open:
- Infant blood levels: No published infant serum measurements were available in LactMed’s August 2026 review.
- Newborn and preterm exposure: The available datasets are too small to establish risk in the youngest or most medically vulnerable infants.
- Effects on milk production or composition: The FDA label states that data on milk production are unavailable.
- Long-term outcomes: Neither study was designed to evaluate growth, neurodevelopment, metabolism, or rare effects over time.
- Higher repeated doses: The FDA-label study used one 5 mg dose; the repeated-dose preprint covered 2.5–5 mg weekly.
- Pregnancy: Lactation studies do not answer pregnancy or fetal-exposure questions.
- Different products: These findings apply to the studied pharmaceutical tirzepatide exposures and cannot establish the identity, purity, concentration, or equivalence of independently supplied or compounded material.
How do these results compare with semaglutide?
Tirzepatide activates both GIP and GLP-1 receptors. Semaglutide is a GLP-1 receptor agonist, so the two drugs should not be treated as interchangeable.
A separate peer-reviewed study sampled milk from eight participants using injectable semaglutide and found no detectable semaglutide at 0, 12, or 24 hours after dosing. That study was also small and had its own timing, dose, assay, and postpartum limitations. It supports the broader need for carefully designed lactation pharmacokinetic studies, not a class-wide safety conclusion.
What do authoritative sources currently say?
The FDA label does not issue a blanket conclusion that tirzepatide is safe during breastfeeding. It says the developmental and health benefits of breastfeeding should be considered alongside the mother’s clinical need and any potential adverse effects on the breastfed infant or from the underlying condition.
LactMed’s August 2026 review says tirzepatide is usually undetectable in breast milk with subcutaneous doses up to 5 mg and that oral absorption by an infant is expected to be limited. It still recommends caution until more data are available, particularly for newborn or preterm infants.
Those are clinical decisions for a patient and qualified healthcare professional. The milk-transfer findings should not be converted into individualized advice to start, stop, or continue treatment.
Bottom line
The best available human evidence suggests that tirzepatide transfer into breast milk is usually below assay detection or present at very low measured levels under the studied conditions. That is more informative than having no human milk data.
It is not the same as proving universal safety. The manufacturer study involved 11 adults and one dose, while the repeated-dosing evidence comes from a five-person, non-peer-reviewed preprint. Infant exposure, milk production, higher steady-state doses, early postpartum use, and long-term outcomes remain incompletely characterized.
For research readers, the careful conclusion is straightforward: the studies measured low milk transfer; they did not settle every clinical safety question.
Frequently asked questions
Was tirzepatide found in breast milk?
In the 11-person single-dose study, tirzepatide was undetectable in 164 of 171 samples and detected at low levels in seven. In the five-person repeated-dose preprint, no sample contained a concentration high enough to quantify reliably.
Does that prove tirzepatide is safe while breastfeeding?
No. Milk concentration is one part of an exposure assessment. The studies were not large or long enough to establish safety for all infants, and the manufacturer study did not expose nursing infants during the post-dose period.
Were pregnant participants included?
No. These were lactation studies involving adults producing breast milk. They do not answer questions about tirzepatide exposure during pregnancy.
Is tirzepatide the same as a GLP-1 drug?
Tirzepatide is a dual GIP and GLP-1 receptor agonist. Semaglutide activates the GLP-1 receptor but not the GIP receptor. Findings for one compound should not automatically be applied to the other.
Can these results be applied to compounded or research material?
No equivalence should be assumed. The studies and FDA label concern defined pharmaceutical exposures. Product identity, concentration, impurities, formulation, and manufacturing controls are separate questions.
Primary and authoritative sources
- FDA prescribing information for Zepbound, section 8.2 Lactation
- ClinicalTrials.gov: NCT05978713 results
- Thompson J, Diab H, Datta P, Krutsch K. Tirzepatide (Zepbound) in Human Milk During Periods of Maternal Dosing (preprint)
- NIH LactMed: Tirzepatide, revised August 15, 2026
- Subcutaneous Semaglutide During Breastfeeding: Infant Safety Regarding Drug Transfer Into Human Milk
Related JD BioWorks resources
- Tirzepatide research evidence: what has actually been studied?
- GLP-2 is not tirzepatide—and “GLP-3” is not retatrutide
- Research Library
This article summarizes published and regulatory research for educational purposes. It is not medical advice and does not provide individualized guidance about pregnancy, breastfeeding, medication use, or infant care. JD BioWorks research materials are for qualified laboratory research only and are not for human or veterinary use.
Related Research Materials
JD-2TR
JD-2TR research material in 10 mg, 20 mg, 40 mg, and 60 mg quantities. Select a quantity to…
View Research Material